SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Integra LifeSciences Holdings Corporation (IART) has a negative trailing P/E of -1.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 4.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -72.01%, forward earnings yield 21.23%. PEG 0.61 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (94/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.61); analyst target implies upside (+35.6%).
- Forward P/E 4.7 — analysts expect a return to profitability with estimated EPS of $2.35 for FY2026.
- PEG Ratio 0.61 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -72.01% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 21.23% as earnings recover.
- Analyst consensus target $15.00 (+35.6% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 46/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
94/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — IART
Valuation Multiples
P/E (TTM)-1.4
Forward P/E4.7
PEG Ratio0.61
Forward PEG0.61
P/B Ratio0.69
P/S Ratio0.45
EV/EBITDA-7.7
Per Share Data
EPS (TTM)$-6.73
Forward EPS (Est.)$2.35
Book Value / Share$13.60
Revenue / Share$21.31
FCF / Share$-0.82
Yields & Fair Value
Earnings Yield-72.01%
Forward Earnings Yield21.23%
Dividend Yield0.00%
Analyst Target$15.00 (+35.6%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
43.0 |
-0.02 |
3.82 |
3.23 |
- |
| 2017 |
58.0 |
-3.41 |
3.90 |
3.16 |
- |
| 2018 |
61.5 |
-5.10 |
2.72 |
2.54 |
- |
| 2019 |
99.4 |
-5.18 |
3.52 |
3.29 |
- |
| 2020 |
41.0 |
0.24 |
3.63 |
4.01 |
- |
| 2021 |
33.6 |
1.26 |
3.37 |
3.68 |
- |
| 2022 |
25.8 |
2.86 |
2.58 |
2.99 |
- |
| 2023 |
50.3 |
-0.84 |
2.14 |
2.21 |
- |
| 2024 |
-251.5 |
2.28 |
1.13 |
1.08 |
- |
| 2025 |
-1.8 |
0.00 |
0.91 |
0.58 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.94 |
$992.08M |
$74.56M |
7.5% |
| 2017 |
$0.82 |
$1.19B |
$64.74M |
5.4% |
| 2018 |
$0.72 |
$1.47B |
$60.8M |
4.1% |
| 2019 |
$0.58 |
$1.52B |
$50.2M |
3.3% |
| 2020 |
$1.57 |
$1.37B |
$133.89M |
9.8% |
| 2021 |
$1.98 |
$1.54B |
$169.08M |
11% |
| 2022 |
$2.16 |
$1.56B |
$180.55M |
11.6% |
| 2023 |
$0.84 |
$1.54B |
$67.74M |
4.4% |
| 2024 |
$-0.09 |
$1.61B |
$-6.94M |
-0.4% |
| 2025 |
$-6.73 |
$1.64B |
$-516.47M |
-31.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$2.35 |
$2.30 – $2.37 |
$1.67B |
$1.65B – $1.68B |
6 |
| 2027 |
$2.56 |
$2.52 – $2.60 |
$1.73B |
$1.72B – $1.74B |
4 |
| 2028 |
$2.72 |
$2.70 – $2.75 |
$1.78B |
$1.78B – $1.78B |
1 |
